Introduction: Although human papillomavirus (HPV) routine vaccination programmes have
been implemented around the world and recommendations have been expanded to include …

Background Effective prophylactic vaccines are available against human papillomavirus
(HPV) types 6, 11, 16, and 18 which are licensed for routine use among young women …

Prophylactic human papillomavirus (HPV) vaccine represents a revolutionary step forward in
preventing HPV-related cancers, especially cervical carcinoma. Alongside appropriate …

The link between human papillomavirus (HPV) infection and different diseases has been
well-established since more than four decades ago [1, 2]. Moreover, high-risk HPV types …

Background Infection with high-risk human papillomavirus (HPV) is causally related to
cervical, vulvar and vaginal pre-invasive neoplasias and cancers. Highly effective vaccines …

Misinformation regarding HPV vaccine safety and benefits has resulted in low coverage
within the eligible French population. HPV vaccination is safe and efficacious in preventing …

Human papillomavirus (HPV) is the most common sexually transmitted infection. The
implementation of primary prevention aims to reduce the burden of HPV infection and HPV …

We currently have the knowledge and experience to prevent much of human papillomavirus
(HPV)-related disease burden globally. In many countries where prophylactic HPV …

Background Human papillomavirus (HPV) vaccination protects against HPV, a necessary
risk factor for cervical cancer. We now report results from population-based follow-up of …

While many European Union/European Economic Area (EU/EEA) countries recently
expanded human papillomavirus (HPV) vaccination to boys, HPV vaccine supply is currently …